PMID: 4288701Dec 1, 1966Paper

Studies on the heterologous immunogenicity of a methanol-insoluble fraction of attenuated tubercle bacilli (BCG). II. Protection against tumor isografts

The Journal of Experimental Medicine
D W WEISSP Leslie

Abstract

A methanol-insoluble residue (MER) of phenol-killed attenuated tubercle bacilli (BCG), which has been reported previously to be capable of evoking heightened resistance to infection with antigenically unrelated microorganisms, was found to affect as well the resistance of highly inbred mice against tumor isografts. In most instances, the MER evoked heightened resistance against the tumor implants, but heightened susceptibility was the effect induced against two of the tumors tested, and no effect was elicited against one neoplasm. It is suggested that the heightened susceptibility occasionally produced by pretreatment with MER may also be of immunological nature, i.e. immunological enhancement. Treatment with MER was more effective when administered some time before tumor challenge than when given simultaneously with, or after, tumor implantation. The protective effects manifested against some tumors were of a high order, a significant number of animals rejecting the neoplastic implants, and were displayed even when several months elapsed between treatment and challenge. Living BCG and intact phenol-killed bacilli also evoked heightened resistance against some of the tumors tested, and in one experiment living BCG proved effect...Continue Reading

References

Dec 1, 1958·Journal of Cellular Physiology. Supplement·G KLEIN, E KLEIN
Jan 1, 1962·Cold Spring Harbor Symposia on Quantitative Biology·H RUBIN
Apr 1, 1963·Transplantation·G I ABELEVI S IRLIN

❮ Previous
Next ❯

Citations

Jan 1, 1978·Journal of Surgical Oncology·W E EnkerR W Wissler
Jan 1, 1977·Biulleten' eksperimental'noĭ biologii i meditsiny·M S LomakinV L Levitina
Dec 23, 1967·Nature·G L Floersheim
Nov 7, 1968·The New England Journal of Medicine·W Brody, J M Criley
Jun 20, 1974·The New England Journal of Medicine·R C BastH J Rapp
Sep 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·A LamensansF M Berger
Oct 14, 1969·Annals of the New York Academy of Sciences·D W Weiss
Feb 1, 1976·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A MantovaniF Spreafico
Jun 8, 1973·Nature·E F OssermanR E Fischel
Aug 1, 1980·Cancer·A Y BedikianG P Bodey
Jun 13, 1973·Nature: New Biology·M S MitchellI Gery
Jun 15, 1975·International Journal of Cancer. Journal International Du Cancer·M MooreN W Nisbet
Dec 1, 1991·DICP : the Annals of Pharmacotherapy·J T Moss, D Kadmon
Jan 15, 1973·International Journal of Cancer. Journal International Du Cancer·S C Bansal, H O Sjögren
Jul 15, 1973·International Journal of Cancer. Journal International Du Cancer·S C Bansal, H O Sjögren
Jan 1, 1994·European Journal of Haematology·R Seljelid, L T Busund
Jan 1, 1969·Journal of Surgical Oncology·R S MyersA S Ketcham
Sep 15, 1973·International Journal of Cancer. Journal International Du Cancer·R W Baldwin, M V Pimm
May 15, 1971·International Journal of Cancer. Journal International Du Cancer·J H CheckK E Fuscaldo
Jul 15, 1975·International Journal of Cancer. Journal International Du Cancer·J W PearsonF S Fuhrman
Jan 1, 1980·Journal of Surgical Oncology·M E ColmerauerY H Pilch
Jul 15, 1974·International Journal of Cancer. Journal International Du Cancer·D O Chee, A J Bodurtha
Jun 15, 1974·International Journal of Cancer. Journal International Du Cancer·R W BaldwinM V Pimm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.